Physician profile
Jessica Hellyer
NPI 1235557398
$14,890.26
in general payments reported to CMS, 2019-2025
38 companies · $2,195 in 2025
The $2,195 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2021: $500 · 2022: $94.53 · 2023: $64.94 · 2024: $12K · 2025: $2,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $2,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,535.00 |
| Food and Beverage | $2,260.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $10,531.95 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,160.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $610.50 | 2021-2024 | Opdivo, Opdualag |
| Pfizer INC. | $584.29 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $361.02 | 2024-2025 | Imfinzi, Enhertu, Calquence |
| Janssen Biotech, INC. | $291.23 | 2022-2025 | Rybrevant, Carvykti, Erleada |
| Novartis Pharmaceuticals Corporation | $174.96 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $154.68 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.19 | 2024-2025 | Iclusig, Alunbrig |
| Merck Sharp & Dohme LLC | $116.65 | 2024-2025 | Keytruda, Reblozyl, Welireg |
| Incyte Corporation | $66.13 | 2024 | Jakafi, Pemazyre, Monjuvi |
| Array Biopharma INC | $64.77 | 2024-2025 | Lorbrena, Braftovi, Xalkori |
| Genentech USA, INC. | $55.18 | 2024-2025 | Tecentriq, Alecensa, Tecentriq Hybreza |
| Mirati Therapeutics, INC. | $52.76 | 2024 | Krazati |
| Celgene Corporation | $51.96 | 2023-2025 | Reblozyl |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $47.89 | 2024-2025 | Ayvakit |
| Fennec Pharmaceuticals, INC. | $45.03 | 2024-2025 | Fyarro, Pedmark |
| Abbvie INC. | $42.30 | 2025 | |
| Syndax Pharmaceuticals, INC. | $34.97 | 2025 | |
| Sobi, INC | $31.16 | 2025 | |
| Iovance Biotherapeutics, INC. | $28.87 | 2025 | Amtagvi |
| Astellas Pharma US INC | $26.80 | 2025 | Vyloy |
| Agios Pharmaceuticals, INC. | $26.71 | 2025 | Pyrukynd |
| Tersera Therapeutics LLC | $24.10 | 2025 | Xermelo |
| Glaxosmithkline, LLC. | $23.15 | 2025 | Jemperli, Zejula |
| Exelixis INC. | $22.96 | 2025 | Cabometyx |
| Lilly USA, LLC | $22.46 | 2025 | Verzenio |
| Puma Biotechnology, INC. | $19.78 | 2024 | |
| Dendreon Pharmaceuticals LLC | $19.07 | 2023 | Provenge |
| Beigene USA, INC. | $16.66 | 2025 | Brukinsa |
| Telix Pharmaceuticals | $16.40 | 2023 | Illuccix |
| Regeneron Healthcare Solutions, INC. | $15.60 | 2024 | Libtayo |
| Gilead Sciences, INC. | $13.08 | 2024 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Hellyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.